An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2015
At a glance
- Drugs Denosumab (Primary) ; Pamidronic acid
- Indications Bone cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Amgen
- 17 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
- 09 Jun 2014 Planned initiation date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 12 May 2014 Planned initiation date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.